„Drug‐Survival“‐Raten und Gründe für den Abbruch von Systemtherapien bei Psoriasis

Mittelschwere bis schwere Psoriasis erfordert häufig eine langfristige systemische Behandlung. Die Therapietreue bezüglich eines Medika‐ments (Überlebensrate, „Drug Survival“) reflektiert dessen Wirksamkeit, Sicherheit sowie die Zufriedenheit mit der Behandlung und ist ein Indikator für den Therapieerfolg. Das Ziel der vorliegenden Studie was die Ermittlung der „Drug‐Survival“‐Raten sowie der Gründe für den Abbruch einer Behandlung mit Fumarsäureestern (fumaric acid esters, FAE), Methotrexat (MTX), Acitretin (ACI), Cyclosporin A (CyA), Adalimumab (ADA), Etanercept (ETA), Infliximab (INF) und Ustekinumab (UST) bei Patienten mit mittelschwerer bis schwerer Psoriasis.

[1]  T. Stanford,et al.  Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective , 2016, The Australasian journal of dermatology.

[2]  M. Augustin,et al.  Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis , 2016, International journal of dermatology.

[3]  A. Steiner,et al.  Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. , 2016, Acta dermato-venereologica.

[4]  G. Murdaca,et al.  Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? , 2016, Expert opinion on drug safety.

[5]  D. Balak,et al.  Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study , 2016, The Journal of dermatological treatment.

[6]  P. Gisondi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  I. Harman-boehm,et al.  Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis. , 2015, Acta Dermato-Venereologica.

[8]  A. Burden,et al.  Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). , 2015, The Journal of investigative dermatology.

[9]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[10]  A. Armstrong,et al.  Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. , 2015, JAMA dermatology.

[11]  L. Skov,et al.  Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris , 2015, The British journal of dermatology.

[12]  R. Romiti,et al.  Ten years on: the impact of biologics on the practice of dermatology. , 2015, Dermatologic clinics.

[13]  M. Seyger,et al.  ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network , 2014, The British journal of dermatology.

[14]  L. Puig,et al.  Long‐term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  F. Nestle,et al.  Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  P. Spuls,et al.  Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single‐centre database analysis , 2014, The British journal of dermatology.

[17]  B. Kirby,et al.  Drug survival of fumaric acid esters for psoriasis: a retrospective study , 2014, The British journal of dermatology.

[18]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[19]  A. Gottlieb,et al.  A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. , 2014, Journal of drugs in dermatology : JDD.

[20]  L. Arends,et al.  The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. , 2014, The Journal of investigative dermatology.

[21]  W. Boehncke,et al.  More than skin-deep: the many dimensions of the psoriatic disease. , 2014, Swiss medical weekly.

[22]  M. Lebwohl,et al.  Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. , 2014, Journal of the American Academy of Dermatology.

[23]  E. Haufe,et al.  Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials , 2014, The British journal of dermatology.

[24]  H. Nakagawa,et al.  Drug survival rates in patients with psoriasis after treatment with biologics , 2013, The Journal of dermatology.

[25]  R. Warren,et al.  Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. , 2013, The Journal of investigative dermatology.

[26]  J. M. Carrascosa,et al.  Acitretina: guía de uso en psoriasis , 2013 .

[27]  S. Chimenti,et al.  Survival rate of antitumour necrosis factor‐α treatments for psoriasis in routine dermatological practice: a multicentre observational study , 2013, The British journal of dermatology.

[28]  F. Vanaclocha,et al.  Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. , 2013, Actas dermo-sifiliograficas.

[29]  W. Weger,et al.  Methotrexate vs. fumaric acid esters in moderate‐to‐severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  P. Gisondi,et al.  Retention rate of systemic drugs in patients with chronic plaque psoriasis , 2013 .

[31]  A. Troxel,et al.  Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. , 2013, Journal of the American Academy of Dermatology.

[32]  Y. Frambach,et al.  Combination of adalimumab with traditional systemic antipsoriatic drugs – a report of 39 cases , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[33]  M. Augustin,et al.  Processes of psoriasis health care in Germany – long‐term analysis of data from the statutory health insurances , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[34]  L. Skov,et al.  Discontinuation of methotrexate in psoriasis. , 2012, Acta dermato-venereologica.

[35]  H. Orzechowski,et al.  S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[36]  C. Massone,et al.  Drug survival rates of biologic treatments in patients with psoriasis vulgaris , 2012, The British journal of dermatology.

[37]  K. Reich,et al.  Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta‐analysis of randomized controlled trials , 2012, The British journal of dermatology.

[38]  L. Skov,et al.  Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris , 2011, The British journal of dermatology.

[39]  J. Barker,et al.  Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study , 2010, The British journal of dermatology.

[40]  A. Gottlieb,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. , 2009, Journal of the American Academy of Dermatology.

[41]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[42]  Å. Svensson,et al.  Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial , 2007, The British journal of dermatology.

[43]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.